48
Views
13
CrossRef citations to date
0
Altmetric
Original Research

The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis

, , , , , , & show all
Pages 3123-3130 | Published online: 22 Jun 2017

References

  • SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
  • AttardGParkerCEelesRAProstate cancerLancet201638710013708226074382
  • HuhtalaMLKahanpääKSeppäläMHalilaHStenmanUHExcretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancyInt J Cancer19833167117146190763
  • RasanenKItkonenOKoistinenHStenmanUHEmerging roles of SPINK1 in cancerClin Chem201662344945726656134
  • TomlinsSAAlshalalfaMDavicioniECharacterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypesEur Urol201568455556725964175
  • TerrySNicolaiewNBassetVClinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancerCancer201512191422143025639219
  • FlavinRPetterssonAHendricksonWKSPINK1 protein expression and prostate cancer progressionClin Cancer Res201420184904491124687926
  • LeinonenKATolonenTTBrackenHAssociation of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancerClin Cancer Res201016102845285120442300
  • SmithSCTomlinsSAProstate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?Clin Cancer Res2016201847334736
  • ZhaoTLiaoBYaoJIs there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?Prostate201575322523225307858
  • SchünemannHJOxmanADVistGEChapter 12: Interpreting results and drawing conclusionsHigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]The Cochrane Collaboration201112.112.20
  • WellsGSheaBO’ConnellDThe Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed March 15, 2016
  • TomlinsSARhodesDRYuJThe role of SPINK1 in ETS rearrange ment-negative prostate cancersCancer Cell200813651952818538735
  • LippolisGEdsjoAStenmanUHBjartellAA high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cellsProstate Cancer Prostatic Dis201316214515023459095
  • GruppKDiebelFSirmaHSPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrenceProstate201373151690169823843146
  • WangCWangLSuBSerine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancerProstate201474768970124619958
  • BrooksJDWeiWHawleySEvaluation of ERG and SPINK1 by immunohistochemical staining and clinicopathological outcomes in a multi-institutional radical prostatectomy cohort of 1067 patientsPLoS One2015107e013234326172920
  • PanXZhangXGongJThe expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancerProstate201676982383327159572
  • NohBJSungJYKimYWChangSGParkYKPrognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancerOncol Lett20161163621363027284364
  • HuangKCEvansADonnellyBBismarTASPINK1 overexpression in localized prostate cancer: a rare event inversely associated with ERG expression and exclusive of homozygous PTEN deletionPathol Oncol Res Epub20161013
  • JohnsonMHRossAEAlshalalfaMSPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at risk, natural history radical prostatectomy cohortJ Urol201619651436144427238617
  • PetterssonAGraffREBauerSRThe TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisCancer Epidemiol Biomarkers Prev20122191497150922736790
  • HuangKCBeginLRPalanisamyNDonnellyBBismarTASPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: implications for biomarker developmentUrol Oncol2015345235.e1e10
  • MukherjiDJabbourMNSaroufimMProgrammed death-ligand 1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: a reliable treatment selection biomarker?Clin Genitourin Cancer201614218318726775720
  • GiraldoNABechtEPagèsFOrchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancerClin Cancer Res201521133031304025688160